| Caprelsa (vandetanib) / Sanofi |
| Completed | 1 | 21 | Europe, RoW | ZD6474 (vandetanib) 100mg, ZACTIMA™, pemetrexed, Alimta®, ZD6474 (vandetanib) 300mg | Genzyme, a Sanofi Company | Carcinoma, Non-Small Cell Lung, Lung Cancer | 05/06 | 10/11 | | |
NCT00507091: Phase I Irinotecan, 5-Fluorouracil and Leucovorin Combination |
|
|
| Completed | 1 | 24 | Europe | ZD6474 (vandetanib) 100mg, ZACTIMA™, Irinotecan, Camptosar®, 5-Fluorouracil, 5-FU, Leucovorin, ZD6474 (vandetanib) 300mg | Genzyme, a Sanofi Company | Metastatic, Colorectal, Adenocarcinoma | 05/06 | 06/08 | | |
| Completed | 1 | 18 | RoW | ZD6474 (vandetanib), ZACTIMA™, 5-Fluorouracil, 5-FU, Leucovorin, Oxaliplatin | Genzyme, a Sanofi Company | Advanced Colorectal Carcinoma | 06/06 | 04/08 | | |
NCT00496275: Phase I Combination With Vinorelbine or Gemcitabine Plus Cisplatin in Locally Advanced or Metastatic NSCLC |
|
|
| Completed | 1 | 17 | Europe | Zactima (ZD6474), Vinorelbine plus cisplatin, Gemcitabine plus cisplatin | Genzyme, a Sanofi Company | Non Small Cell Lung Cancer | | 05/07 | | |
NCT00681798: Dose Escalation Study With Zactima and Chemotherapy in Metastatic Pancreas Carcinoma |
|
|
| Completed | 1 | 8 | Europe | Vandetanib, Zactima | Sanofi | Pancreatic Cancer | 06/09 | 06/09 | | |
NCT00937417: S0716 Vandetanib and Docetaxel in Treating Patients With Advanced Solid Tumors |
|
|
| Withdrawn | 1 | 0 | NA | docetaxel, vandetanib, proteomic profiling, laboratory biomarker analysis, pharmacological study | Southwest Oncology Group, National Cancer Institute (NCI) | Breast Cancer, Head and Neck Cancer, Lung Cancer, Prostate Cancer, Unspecified Adult Solid Tumor, Protocol Specific | 09/09 | 09/09 | | |
NCT00450138: Open Label, Phase I ZD6474 Head and Neck Cancer Study |
|
|
| Completed | 1 | 48 | US | ZD6474 (vandetanib), ZACTIMA™, Cisplatin, Radiation | Sanofi | Head and Neck Cancer | 11/09 | 11/11 | | |
|
NCT00807170: Investigate the Maximum Tolerated Dose of Vandetanib and Concurrent Whole Brain Radiotherapy (WBRT) in Patients With Non-small Cell Lung Cancer (NSCLC) and Brain Metastases |
|
|
| Terminated | 1 | 5 | Europe | ZD6474 (Vandetanib), ZACTIMA TM, Whole Brain Radiotherapy (WBRT), ZD6474 | Sanofi | Non-small Cell Lung Cancer (NSCLC) | 08/10 | 08/10 | | |
NCT01004419: Trial of ZD6474 and Faslodex in Non-Small Cell Lung Cancer |
|
|
| Withdrawn | 1 | 0 | US | ZD6474 (vandetanib), ZD6474, Zactima, Faslodex (Fulvestrant), Faslodex | University of Wisconsin, Madison, AstraZeneca, University of Pittsburgh | Carcinoma, Non Small Cell Lung | 11/10 | 05/11 | | |
NCT00745732: Radiation Therapy (XRT) and ZD6474 in Non-Small Cell Lung Cancer (NSCLC) |
|
|
| Terminated | 1 | 3 | US | ZD6474 (ZACTIMA), Zactima, Vandetanib, Radiation Therapy, Radiation, XRT | M.D. Anderson Cancer Center, AstraZeneca | Non-Small Cell Lung Cancer | 09/12 | 09/12 | | |
NCT01539655: Study in Healthy Volunteers to Assess Effect of Omeprazole and Ranitidine on the Pharmacokinetics of Vandetanib |
|
|
| Completed | 1 | 34 | US | vandetanib, omeprazole, ranitidine | Sanofi | Medullary Thyroid Cancer | 09/12 | 09/12 | | |
